Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 1, 2011, Pages 117-125

  Dobrinas, M ^a   Cornuz, J ^b   Oneda, B ^a,c   Kohler Serra, M ^b   Puhl, M ^b   Eap, C B ^a,d  

^a Hopital de Cery   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; DRUG METABOLIZING ENZYME; PARAXANTHINE;

ADULT; ARTICLE; CIGARETTE SMOKING; CONTRACEPTION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING CESSATION;

ADULT; AGE FACTORS; COTININE; CYTOCHROME P-450 CYP1A2; ENZYME INDUCTION; FEMALE; HAPLOTYPES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; POLYMORPHISM, GENETIC; SEX FACTORS; SMOKING; SMOKING CESSATION; YOUNG ADULT;

EID: 79959375989     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.70     Document Type: Article

References (39)

1. Kroon, L.A. Drug interactions with smoking. Am. J. Health. Syst. Pharm. 64, 1917-1921 (2007). (Pubitemid 47462906)
2. Zhou, S.F., Wang, B., Yang, L.P. & Liu, J.P. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev. 42, 268-354 (2010).
3. Eap, C.B. et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J. Clin. Psychopharmacol. 24, 214-219 (2004). (Pubitemid 38380846)
4. van der Weide, J., Steijns, L.S. & van Weelden, M.J. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13, 169-172 (2003). (Pubitemid 36324246)
5. Carrillo, J.A., Herráiz, A.G., Ramos, S.I., Gervasini, G., Vizcaíno, S. & Benítez, J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J. Clin. Psychopharmacol. 23, 119-127 (2003). (Pubitemid 36368788)
6. Spigset, O., Carleborg, L., Hedenmalm, K. & Dahlqvist, R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin. Pharmacol. Ther. 58, 399-403 (1995).
7. Zevin, S. & Benowitz, N.L. Drug interactions with tobacco smoking. An update. Clin. Pharmacokinet. 36, 425-438 (1999). (Pubitemid 29317490)
8. Miller, D.D., Kelly, M.W., Perry, P.J. & Coryell, W.H. The influence of cigarette smoking on haloperidol pharmacokinetics. Biol. Psychiatry 28, 529-531 (1990). (Pubitemid 20298446)
9. MacLeod, S., Sinha, R., Kadlubar, F.F. & Lang, N.P. Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat. Res. 376, 135-142 (1997). (Pubitemid 27248596)
10. Meyer, J.M. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J. Clin. Psychopharmacol. 21, 569-574 (2001). (Pubitemid 33116655)
11. Zullino, D.F., Delessert, D., Eap, C.B., Preisig, M. & Baumann, P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int. Clin. Psychopharmacol. 17, 141-143 (2002). (Pubitemid 34442196)
12. Oyewumi, L.K. Smoking cessation and clozapine side effects. Can. J. Psychiatry. 43, 748 (1998). (Pubitemid 28522733)
13. McCarthy, R.H. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 27, 210-211 (1994). (Pubitemid 24291953)
14. Skogh, E., Bengtsson, F. & Nordin, C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther. Drug Monit. 21, 580-582 (1999). (Pubitemid 29468329)
15. Dobrinas, M., Cornuz, J., Kohler Serra, M., Puhl, M. & Eap, C.B. [Genetic aspects of smoking and impact on clinical care]. Rev. Med. Suisse 5, 1463-1467 (2009).
16. Faber, M.S. & Fuhr, U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin. Pharmacol. Ther. 76, 178-184 (2004). (Pubitemid 39013407)
17. Schrenk, D., Brockmeier, D., Mörike, K., Bock, K.W. & Eichelbaum, M. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur. J. Clin. Pharmacol. 53, 361-367 (1998). (Pubitemid 28067979)
18. Tantcheva-Poór, I., Zaigler, M., Rietbrock, S. & Fuhr, U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a salivabased caffeine test. Pharmacogenetics 9, 131-144 (1999). (Pubitemid 29358995)
19. Landi, M.T., Sinha, R., Lang, N.P. & Kadlubar, F.F. Human cytochrome P4501A2. IARC Sci. Publ. 148:173-195. (1999).
20. Nakajima, M., Yokoi, T., Mizutani, M., Kinoshita, M., Funayama, M. & Kamataki, T. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. 125, 803-808 (1999). (Pubitemid 29192503)
21. Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J. & Kamataki, T. Detection of three genetic polymorphisms in the 5-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn. J. Cancer Res. 90, 899-902 (1999). (Pubitemid 29500425)
22. Murayama, N. et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J. Pharmacol. Exp. Ther. 308, 300-306 (2004). (Pubitemid 38090731)
23. Sachse, C., Brockmöller, J., Bauer, S. & Roots, I. Functional significance of a C-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47, 445-449 (1999). (Pubitemid 29161279)
24. Han, X.M. et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 11, 429-435 (2001).
25. Gunes, A. et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 10, 769-778 (2009).
26. Ghotbi, R., Christensen, M., Roh, H.K., Ingelman-Sundberg, M., Aklillu, E. & Bertilsson, L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol. 63, 537-546 (2007). (Pubitemid 46684487)
27. Pavanello, S., Pulliero, A., Lupi, S., Gregorio, P. & Clonfero, E. Influence of the genetic polymorphism in the 5-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat. Res. 587, 59-66 (2005). (Pubitemid 41503581)
28. Service de pharmacologie et toxicologie clinique, Hôpitaux Universitaires Gèneve. Interactions medicamenteuses et cytochrome P450 (2010).
29. Ito, K. et al. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4, E25 (2002).
30. Krusekopf, S., Roots, I., Hildebrandt, A.G. & Kleeberg, U. Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/ K+ -ATPase inhibitors and other xenobiotics. Xenobiotica. 33, 107-118 (2003). (Pubitemid 36237934)
31. Simon, T. et al. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br. J. Clin. Pharmacol. 52, 601-604 (2001).
32. Kashuba, A.D. et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin. Pharmacol. Ther. 63, 540-551 (1998). (Pubitemid 28277275)
33. Nebert, D.W., Dalton, T.P., Okey, A.B. & Gonzalez, F.J. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 279, 23847-23850 (2004). (Pubitemid 38725238)
34. Bondolfi, G., Morel, F., Crettol, S., Rachid, F., Baumann, P. & Eap, C.B. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther. Drug Monit. 27, 539-543 (2005). (Pubitemid 41098833)
35. Schweikl, H., Taylor, J.A., Kitareewan, S., Linko, P., Nagorney, D. & Goldstein, J.A. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3, 239-249 (1993). (Pubitemid 23333093)
36. Ou-Yang, D.S. et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br. J. Clin. Pharmacol. 49, 145-151 (2000).
37. Faber, M.S., Jetter, A. & Fuhr, U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin. Pharmacol. Toxicol. 97, 125-134 (2005). (Pubitemid 41291208)
38. Gunes, A. & Dahl, M.L. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 9, 625-637 (2008). (Pubitemid 351803920)
39. Soyama, A. et al. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab. Pharmacokinet. 20, 24-33 (2005).